ARK Diagnostics Inc (ARK Diagnostics) is a developer, manufacturer and commercializer of in vitro diagnostic immunoassay products. The company's products include protease inhibitors, levetiracetam assay, topiramate assay, non-nucleoside reverse transcriptase inhibitors, gabapentin assay, lamotrigine assay, fentanyl assay, zonisamide assay, methotrexate assay, thyroxine assay and entry inhibitor, among others. Its products are used in the therapeutic areas of epilepsy, pain management, cancer, urine tests, veterinary, and HIV or AIDS. ARK Diagnostics's protease inhibitors include ritonavir, darunavir, saquinavir, amprenavir, lopinavir, atazanavir, indinavir and tipranavir. The company's immunoassays measure drug levels in biological fluids that enable clinicians to guide dosing decisions for drug therapy. It distributes its products across Germany, Austria, Belgium, the Netherlands, Luxembourg, the UK and Ireland. ARK Diagnostics is headquartered in Fremont, California, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
The report analyzes all pipeline products in development for the company ARK Diagnostics Inc
The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
The report provides detailed description of products in development, technical specification and functions
The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
To formulate effective Research & Development strategies
Develop market-entry and market expansion strategies
Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note:Some sections may be missing if data is unavailable for the company
ARK Diagnostics Inc Company Overview
ARK Diagnostics Inc Company Snapshot
ARK Diagnostics Inc Pipeline Products and Ongoing Clinical Trials Overview
ARK Diagnostics Inc – Pipeline Analysis Overview
ARK Diagnostics Inc - Key Facts
ARK Diagnostics Inc - Major Products and Services
ARK Diagnostics Inc Pipeline Products by Development Stage
ARK Diagnostics Inc Pipeline Products Overview
ARK Apixaban Assay
ARK Apixaban Assay Product Overview
ARK Atazanavir Assay
ARK Atazanavir Assay Product Overview
ARK Dabigatran Assay
ARK Dabigatran Assay Product Overview
ARK Darunavir Assay
ARK Darunavir Assay Product Overview
ARK Dolutegravir Assay
ARK Dolutegravir Assay Product Overview
ARK Edoxaban Assay
ARK Edoxaban Assay Product Overview
ARK High Sensitivity Opiates Assay
ARK High Sensitivity Opiates Assay Product Overview
ARK Indinavir Assay
ARK Indinavir Assay Product Overview
ARK Lopinavir Assay
ARK Lopinavir Assay Product Overview
ARK Maraviroc Assay
ARK Maraviroc Assay Product Overview
ARK Nelfinavir Assay
ARK Nelfinavir Assay Product Overview
ARK Nevirapine Assay
ARK Nevirapine Assay Product Overview
ARK Perampanel Assay
ARK Perampanel Assay Product Overview
ARK Rivaroxaban Assay
ARK Rivaroxaban Assay Product Overview
ARK Saquinavir Assay
ARK Saquinavir Assay Product Overview
ARK Tiagabine Assay
ARK Tiagabine Assay Product Overview
ARK Zolpidem Assay
ARK Zolpidem Assay Product Overview
ARK Zopiclone Assay
ARK Zopiclone Assay Product Overview
ARK Diagnostics Inc - Key Competitors
ARK Diagnostics Inc - Key Employees
ARK Diagnostics Inc - Locations And Subsidiaries
Head Office
Recent Developments
ARK Diagnostics Inc, Recent Developments
Jan 04, 2024: ARK Diagnostics Receives 510(K) Clearance For Methotrexate II Assay
Nov 22, 2023: ARK Diagnostics Receives 510(K) Clearance For ARK Hydrocodone Assay
Aug 10, 2021: ARK Diagnostics receives 510(k) clearance for ARK Lacosamide Assay
Jul 06, 2021: Orient Gene won the lawsuit in the Section 337 Investigation of Gabapentin immunoassay products
Jan 15, 2020: Siemens Healthineers adds fentanyl assay to its menu to help laboratories address greater demand for opioid testing
Oct 17, 2014: Roche to integrate Methotrexate test from ARK Diagnostics into therapeutic drug monitoring menu for clinical chemistry analyzers